<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441363</url>
  </required_header>
  <id_info>
    <org_study_id>165-AD-04-03-US-2</org_study_id>
    <nct_id>NCT00441363</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group Trial to Assess the Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VeroScience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VeroScience</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of Cycloset® and placebo
      when added to metformin monotherapy (at least 1000 mg/day for 3 months prior to screening) in
      persons with type 2 diabetes mellitus who are not adequately controlled on metformin therapy
      alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the previously conducted Phase III clinical trials, Cycloset® (up to a maximum dose of 4.8
      mg/day), administered either as monotherapy or combined with sulfonylurea therapy,
      significantly reduced HbA1c, fasting and post-prandial glucose and fasting and post-prandial
      triglycerides in obese individuals with type 2 diabetes mellitus. Clinical studies that
      combined Cycloset® with metformin were not as part of the original Cycloset® clinical program
      because metformin was not commercially available in the United States at the time that the
      studies were initiated. The present study is designed to investigate the efficacy and safety
      of Cycloset® compared to placebo when added to metformin monotherapy in persons with type 2
      diabetes mellitus who are not adequately controlled on metformin therapy alone.

      A sufficient number of individuals will be screened to enroll up to 326
      subjects;approximately 276 subjects are expected to complete treatment through study
      termination (Week 26). The study population will consist of individuals currently treated
      with metformin, for at least 3 months prior to the study start. Subjects who have ever
      received exogenous insulin therapy as part of an outpatient diabetes treatment regimen are to
      be excluded, as are those taking oral anti-diabetic agents other than metformin within 3
      months of screening (e.g., sulfonylureas, thiazolidinediones,alpha-glucosidase inhibitors, or
      meglitinides). Subjects may be male or female(surgically sterile, postmenopausal, or using
      appropriate contraceptive methods if of childbearing potential), age 18 to 75 years,
      inclusive, and are to have a screening HbA1c value of ≥ 7.5% and &lt;11.0% and a screening body
      mass index (BMI) in the range of 25 kg/m2 to 42 kg/m2, inclusive.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to Recruit in a Timely manner
  </why_stopped>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Baseline to End of Study in HbA1c</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Too few subjects were enrolled to assess outcome to pre-specified statistical power.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose and Lipids</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events Experienced by the Subjects</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Bromocriptine Mesylate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bromocriptine mesylate 0.8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bromocriptine mesylate 0.8 mg matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromocriptine Mesylate</intervention_name>
    <description>0.8 mg tablet</description>
    <arm_group_label>Bromocriptine Mesylate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cycloset</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with type 2 diabetes mellitus, for at least six months prior to screening.

          2. 18-75 years of age, inclusive.

          3. Male or if female, is either:

               -  postmenopausal or

               -  of childbearing potential and has used appropriate contraceptive methods

          4. Treated with a stable dose of metformin at least 3 months.

          5. Has not been treated with a sulfonylurea, thiazolidinedione, meglitinide,
             alpha-glucosidase inhibitor, or combination oral anti-diabetic therapy within 3 months
             prior to screening.

          6. Has not been on a regimen of lipid-lowering agents or if on such a regimen, it has
             been stable for a minimum of 6 weeks at screening.

          7. HbA1c value between ≥ 7.5% and &lt; 11%, at screening (Visit 1) and Visit 3.

          8. Fasting plasma glucose measurement of ≤260 mg/dL at screening (Visit 1) and Visit 3.

          9. Fasting C-peptide value equal to or greater than the normal accepted minimum value
             (e.g. &lt; 0.9 NG/ml).

         10. Stable body weight, i.e., not varying by &gt; 10% for at least3 months prior to screening

         11. Body mass index (BMI) at screening of 25 kg/m2 to 42 kg/m2,inclusive.

         12. If treated for hypertension, the individual has been on stable therapy for 1 month
             prior to screening.

        Exclusion Criteria:

          1. Prior exogenous insulin therapy as part of an outpatient diabetes treatment regimen.

          2. Type 1 diabetes mellitus

          3. Clinically significant history of cardiac disease or presence of cardiac disease,
             including MI, clinically significant arrhythmia, unstable angina pectoris, moderate to
             severe congestive heart failure, CABG, or angioplasty; or expected to require CABG or
             angioplasty during the study.

          4. Uncontrolled hypertension, defined as systolic blood pressure &gt; 160 or diastolic blood
             pressure &gt; 100 mmHg measured in sitting position at screening(Visit 1)

             Clinically significant history or presence of:

          5. Hepatic disease (i.e. impaired liver function, including having AST or ALT greater
             than three times the upper limit of normal)

          6. Renal disease (i.e. renal impairment with a serum creatinine ≥ 1.4 mg/dl)

          7. Central nervous system disease, including epilepsy

          8. CVA within the last 3 years.

          9. Less than 5 years remission from clinically significant malignancy.

         10. Major surgical operation within 3 months of screening.

         11. Organ transplantation.

         12. Evidence of acute or chronic illness including known or suspected HIV,HBV, or HCV
             infection.

         13. Currently abuses drugs or alcohol, including binge drinking, or history of abuse that
             in the investigator's opinion would cause the individual to be noncompliant.

         14. Regularly uses medications with addictive potential such as opiates,narcotics,
             tranquilizers, etc.

         15. Used drugs for weight loss, e.g., Xenical® (orlistat), Meridia® (sibutramine),Acutrim®
             (phenylpropanolamine), or similar over-the-counter medications within 3 months of
             screening.

         16. Known hypersensitivity to any components of the study drugs.

         17. Received any experimental drug or used an experimental device within 3 months of
             screening or will do so during the study.

         18. Has received unstable dose of fibric acid derivatives within 3 months of the
             screening.

         19. Requires regular use of systemic corticosteroids by oral, intravenous (IV),or
             intramuscular (IM) route, or regular use of potent, inhaled intranasal steroids that
             are known to have a high rate of systemic absorption.

         20. Prescription sympathomimetic drugs within 7 days of screening.

         21. Started therapy with an erectile dysfunction drug within 2 weeks prior to screening.
             The subject may not begin treatment with an erectile dysfunction drug during the study
             period; subjects previously taking erectile dysfunction drugs should do so only under
             medical supervision.

         22. Donated blood within 60 days of screening. Donation of blood also is prohibited during
             the study and for 30 days after completion of the study.

         23. Occupation that requires a rotation of shift work or working over night shifts.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E Scranton, MD</last_name>
    <role>Study Director</role>
    <affiliation>VeroScience</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2007</study_first_submitted>
  <study_first_submitted_qc>February 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2007</study_first_posted>
  <results_first_submitted>November 8, 2010</results_first_submitted>
  <results_first_submitted_qc>April 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 9, 2016</results_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Bromocriptine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was originally designed to enroll 326 subjects in order to randomize 225 subjects. Due to a strategic business decision of the former sponsor (PLIVA), enrollment into the study was prematurely terminated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cycloset</title>
          <description>0.8 mg tablet</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15">no subject withdrew early since the trial was terminated</participants>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cycloset</title>
          <description>0.8 mg tablet</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="10.5"/>
                    <measurement group_id="B2" value="53" spread="9.3"/>
                    <measurement group_id="B3" value="53" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Baseline to End of Study in HbA1c</title>
        <description>Too few subjects were enrolled to assess outcome to pre-specified statistical power.</description>
        <time_frame>up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycloset</title>
            <description>0.8 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline to End of Study in HbA1c</title>
          <description>Too few subjects were enrolled to assess outcome to pre-specified statistical power.</description>
          <units>% HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread=".95"/>
                    <measurement group_id="O2" value="-.5" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose and Lipids</title>
        <time_frame>up to 24 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Serious Adverse Events Experienced by the Subjects</title>
        <time_frame>up to 24 weeks</time_frame>
        <population>Report of Serious adverse events that occurred in the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Cycloset</title>
            <description>0.8 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events Experienced by the Subjects</title>
          <population>Report of Serious adverse events that occurred in the trial.</population>
          <units>serious adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cycloset</title>
          <description>0.8 mg tablet</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>unstable angina</sub_title>
                <description>The only SAE in the study was reported in a subject from the Cycloset™ treatment group who experienced unstable angina and dyspnea. Both events were deemed by the site investigator as unlikely related to study drug and resolved.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Donna Cowan</name_or_title>
      <organization>VeroScience</organization>
      <phone>401 816-0525</phone>
      <email>donna_cowan@veroscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

